Market News & Trends
Abeona Therapeutics Uses Next-Generation AAV-Based Gene Therapy
Adeno-Associated Virus (AAV) vectors are currently among the most frequently used viral vectors for gene therapy. At recent meetings of the American Society for Gene…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
LEO Pharma Enters Biologics Through Strategic Partnership With AstraZeneca
LEO Pharma recently announced it is a significant step closer to realizing its vision of becoming the preferred dermatology care partner following a strategic partnership…
Tesaro Raises $377 Million
TESARO, Inc. recently announced it has commenced an underwritten public offering of $300 million of its common stock. In connection with this offering, TESARO plans…
Merck Provides Results of Pivotal Study That Confirms Addition of Erbitux to FOLFOX Significantly Improves Outcomes
Merck presented data at the ESMO 18th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, the…
Aeterna Zentaris & Orient Europharma Sign License Agreement
Aeterna Zentaris Inc. and Orient EuroPharma Co., Ltd. recently announced the signing of an exclusive license agreement between the company and Cyntec Co., Ltd., an…
RiboMed Biotechnologies & Tocagen Collaborate to Analyze Epigenetic Prognostic Markers, Including MGMT, in Recurrent Brain Tumors
RiboMed Biotechnologies, Inc. and Tocagen Inc. recently announced a collaboration to analyze potential epigenetic prognostic and predictive markers, including the gene for the DNA repair…
Relmada Therapeutics Secures First European Patent Covering LevoCap ER
Relmada Therapeutics, Inc. recently announced it has been granted a patent from the European Patent Office (EPO) for compositions and methods of use for its…
West’s SmartDose(®) Drug Delivery Technology Platform Selected by Amgen for Pushtronex™ System
On-body Infusor with Prefilled Cartridge to Deliver Monthly Single Dose of Repatha® (evolocumab) West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in…
Global Urological Cancers Market Will Double to $35.9 billion by 2022
The urological cancers market, including bladder, kidney, prostate, and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a…
Everon Biosciences Introduces New Age-Related Cellular Target That Changes Focus of Anti-Aging Drug Discovery
A research team from Everon Biosciences, Inc. and Roswell Park Cancer Institute has identified a specific subpopulation of immune cells accumulating in old mice that…
BeiGene Announces Initiation of a Combination Trial of the BTK Inhibitor BGB-3111 With the PD-1 Antibody BGB-A317
BeiGene, Ltd. recently announced the dosing of the first patient in a Phase I clinical trial of BGB-3111, a Bruton’s tyrosine kinase (BTK) inhibitor, in…
Biogen & AbbVie’s Once-Monthly ZINBRYTA Approved in European Union
The European Commission (EC) has granted marketing authorization for ZINBRYTA (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen…
Intrexon & ZIOPHARM Amend Exclusive Channel Collaborations
Intrexon Corporation and ZIOPHARM Oncology, Inc. recently announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve…
Intra-Cellular Therapies Reports Completion of Enrollment of Phase III Clinical Trial
Intra-Cellular Therapies, Inc. recently announced completion of enrollment in the second Phase III clinical trial (ITI-007-302) of the company's lead product candidate ITI-007 for the…
